文献速递膀胱癌与上尿路尿路上皮癌

热灌注丝裂霉素C治疗中危非肌层浸润性膀胱癌:HIVEC-1试验结果

Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
PubMed 文献 · Eur Urol Oncol · 2022-11-23

HIVEC-1是一项在西班牙13个中心开展的前瞻性开放标签3期随机对照试验,纳入中危非肌层浸润性膀胱癌患者,比较常温与43°C热灌注丝裂霉素C(30或60分钟)的疗效。意向治疗人群24个月无复发生存率常温组77%、43°C-30分钟组82%、43°C-60分钟组80%(p=0.6),热灌注未优于常温灌注。

要点

  • 意向治疗人群24个月无复发生存率三组分别为77%、82%、80%,差异无统计学意义(p=0.6)。
  • 严重不良事件发生于26例患者(8.1%),组间无差异(p=0.5)。
  • 不良事件主要为排尿困难和痉挛,总发生率33%至48%(p=0.05)。

核心结论

  • 使用COMBAT系统进行4个月辅助热灌注丝裂霉素C(43°C,30或60分钟)治疗中危非肌层浸润性膀胱癌耐受性良好,但24个月时未发现优于常温丝裂霉素C。

研究设计与样本

  • 前瞻性开放标签3期随机对照试验(HIVEC-1),2014年至2020年在西班牙13个中心入组。
  • 患者在接受膀胱完全经尿道切除及术后即刻丝裂霉素C灌注后,按1:1:1随机分为常温对照组(n=106)、43°C-30分钟组(n=107)和43°C-60分钟组(n=106)。
  • 治疗方案为每周4次后每月3次40 mg丝裂霉素C灌注;治疗依从性定义为完成4次或以上灌注。

主要发现

  • 意向治疗人群24个月无复发生存率:对照组77%,43°C-30分钟组82%,43°C-60分钟组80%(p=0.6)。
  • 符合方案人群24个月无复发生存率:对照组77%,43°C-30分钟组83%,43°C-60分钟组80%(p=0.59)。
  • 意向治疗人群中6例进展为肌层浸润性疾病(对照组、43°C-30分钟组和43°C-60分钟组各4例,原文此处表述有矛盾);符合方案人群中4例进展(均为对照组)。
  • 严重不良事件发生于26例患者(8.1%),组间无差异(p=0.5)。
  • 不良事件(主要为排尿困难和痉挛)发生于124例患者(对照组33%,43°C-30分钟组35%,43°C-60分钟组48%;p=0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,热灌注丝裂霉素C在24个月时未优于常温丝裂霉素C。
  • 原文患者总结指出,长期复发和进展以及维持方案的进一步评估似乎是必要的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimising therapeutic strategies of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) is needed. OBJECTIVE: To compare recurrence-free survival (RFS) with adjuvant intravesical mitomycin C (MMC) at normothermia or hyperthermia using the COMBAT bladder recirculation system at 43 °C for 30 and 60 min. DESIGN, SETTING, AND PARTICIPANTS: A prospective open-label, phase 3 randomised controlled trial (HIVEC-1) accrued across 13 centres between 2014 and 2020 in Spain. After complete transurethral resection of the bladder and immediate postoperative MMC instillation, patients with IR-NMIBC were randomised (1:1:1) to four weekly followed by three monthly 40-mg MMC instillations at normothermia (control; n = 106), 43 °C for 30 min (n = 107), or 43 °C for 60 min (n = 106) were investigated. Therapeutic compliance was defined as four or more instillations. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was RFS at 24 mo in the intention-to-treat (ITT) and per-protocol (PP) populations. The secondary outcomes included progression-free survival at 24 mo, safety outcome measures, and changes in health-related quality of life. Log-rank, Fisher, χ2, and analysis of variance tests were used. RESULTS AND LIMITATIONS: The ITT 24-mo RFS was 77% for control, 82% for 43 °C-30 min, and 80% for 43 °C-60 min (p = 0.6). The PP 24-mo RFS was 77% for control, 83% for 43 °C-30 min, and 80% for 43 °C-60 min (p = 0.59). Six patients progressed to muscle-invasive disease in the ITT population (four in the control, 43 °C-30 min, and 43 °C-60 min groups each) and four in the PP population (all controls). Serious adverse events occurred in 26 patients (8.1%), and we were unable to demonstrate a difference between groups (p = 0.5). Adverse events, mainly dysuria and spasms, occurred in 124 patients (33% in control, 35% in 43 °C-30 min, and 48% in 43 °C-60 min; p = 0.05). The total International Prostate Symptom Score worsened by 1.2 ± 7.3 points, similarly across groups (p = 0.29). The Functional Assessment of Cancer Therapy-Bladder domains and indexes showed no significant change. CONCLUSIONS: Four-month adjuvant hyperthermic MMC using the COMBAT system for 30 and 60 min in IR-NMIBC is well tolerated, but we did not find it to be superior to normothermic MMC at 24 mo. PATIENT SUMMARY: We were unable to demonstrate the effectiveness of hyperthermia using the COMBAT system in intermediate-risk non-muscle-invasive bladder cancer. Further evaluation of long-term recurrence and progression, and maintenance regimens appears mandatory.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2022. PMID: 36435738. doi:10.1016/j.euo.2022.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。